TAPROS Leuprorelin acetate

Tapros, For uterine myomas, Effective, Convenient, Trusted

Therapeutic Indications.
- Treatment of prostatic cancer with metastate.
- Treatment of endometriosis at genital and extragenital localizatio (from stage I to
stage IV)
The clinical knowledge concerning the endrometriosis treatment is limited to woman
over 18 years old.
The treatment duration is limited to 6 months.
- Pre-operative management of uterine myoma (fibroid) to reduce their size and
associated bleeding.
- Treatment of central precocious puberty.

It is not recommended to start a second treatment period with TAPROS or with another Gn-RH analogue.

Dosage and mode of administration.
- Prostatic cancer
One Subcutaneous injetion which will be renewed every four weeks.
- Endometriosis
Usually, for adults, 3.75 mg of leuprorelin acetate is administered subcutaneously
or intramuscularly once every 4 weeks for period of 6 months only.
- However, when the patient's weight is less than 50 kg. 1.88 preparation may be
used.
The treatment should start during the five first days of the menstrual cycle.
- Uterine myoma (fibroid)
One subcutaneous or intramuscular injection will be renewed every 4 weeks.
The treatment should start during the five first days of the menstrual cycle.
- Central precocious puberty
Usually, a dose of 30 mg/kg administer subcutaneosly once every 4 weeks.
Depending Upon the patient's condition, the dosage may be increased up to 90 mg/kg
The safety of TAPROS in prematures, newborns, and nursing infants has not been
established.

Contraindications.
- Hypersensitivity to Gn-RH, to Gn-RH analogues or to one of the components.
- Vaginal bleedings of non determined origin.